{"name":"Castle Creek Pharmaceuticals, LLC","slug":"castle-creek-pharmaceuticals-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBScXRtQ0tnTHAtQ1RNeTQwUm9HcmNXWXVJUzg0NGo4b2dUVnVYSS01ekpBUlpXa1J0bDlpWlhham5ubzhYZXh4dW5yanlVR19ZSnc?oc=5","date":"2025-06-06","type":"trial","source":"Endpoints News","summary":"IPO Tracker (2021) - Endpoints News","headline":"IPO Tracker (2021)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOZ2ZCSGFOLV9qbUhsdDJVdnA0MTNPdFpUZENOS1RRQWFNUmppYkpoX2hXYWNObTNFejRFekdWVXBlZ3pBTm1SZUE2NHE4amNISGhHUmRWTXJRSmFhR2NReThueUFHX19EMll6bWdzVVZGa3E5Z283cGEzU0tyUDdBYTg2UmxWZGRmNVB3T2xoV0p3M2pjQmRjbE5idTRnQlJRX1Zrekgtc1VvYzZ2SEp2UGJOTGdWUUQwckRQdGpCUlI4SmdvS2pHRHhaSDhsYUJyczQzT2otVUY?oc=5","date":"2025-02-25","type":"pipeline","source":"GlobeNewswire","summary":"Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences - GlobeNewswire","headline":"Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOUzJRNVJ3bDQzNm1yRGlyLUpUUmctUUVwT3ZPZUZOM1NwaXQtMXBySzhVX2xtcTFjcV9pNTdDd3BRWEI0dURCZWpMbzZlVVJkQjVlY2dlQmJuVlJ3Y3VnVWVXajV6MjlwWGZSODk0NTZER2x2ZVBkNkh1bUxCQm1Md3lHclA0NUdncHlQeERaNjREOFdOWFpaVFpB?oc=5","date":"2020-05-09","type":"pipeline","source":"Philadelphia Magazine","summary":"9 Philly Companies on the Cutting Edge of Cell and Gene Therapy Innovation - Philadelphia Magazine","headline":"9 Philly Companies on the Cutting Edge of Cell and Gene Therapy Innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQZmFabDNiakptd1hqeXJ1cjUtMUlLRUtjQks4aEN6OHRjUWhfZTRQdDE1alhzWnNWZUxUMUtfYl8ycUNsWE52SEZqMV9DUU9iaWp6VDU4anJYSzBDUkE1VjJnT0hxa3h4Y2pyTlhCZlQzek9nY1ZFMGRfTDdRRDdGSEluSDBLd0JlY3RpUEtQb3duSEYzUVZLOGNtM3J2SnR3b1FYenBxdGVUN3hE?oc=5","date":"2019-04-22","type":"pipeline","source":"Fierce Biotech","summary":"Former Alkermes COO Robinson to head up ops at Paragon Biosciences - Fierce Biotech","headline":"Former Alkermes COO Robinson to head up ops at Paragon Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQbjNLMUh1dzBoZzBEanNXWFBobkRuZlRZX2ZSa2NyRWFVdTVPQUVQMURpMUhzQk11RWNEYnNkS0lSMEN4NXk1cGpCNWtvcy1nMGRWb3k1T3RFMHFIU1ZWVFZSZ1B6amxsZlZ1WTFIbkIyN0JNVVFmT2FxVHRQaEEwV3RwTHNvcENvanZLOThFandQeTdmb2Y1TENxcVZsTkdVT3pHczE3YjJYYTUtZEo2dEtFOA?oc=5","date":"2019-04-15","type":"pipeline","source":"Fierce Biotech","summary":"Fibrocell, Castle Creek ink rare disease gene therapy pacts worth up to $135M - Fierce Biotech","headline":"Fibrocell, Castle Creek ink rare disease gene therapy pacts worth up to $135M","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}